Watchlist · 78/100Oct 22, 1:18 PM EDT
Argenx Targets $4B OpEx by 2026, Eyes Five U.S. Launches in 2027
ARGNFARGX
Argenx outlined 2026 operating expenses of approximately $4 billion as it prepares for up to five U.S. product launches in 2027. The company highlighted that VYVGART is still early in its launch trajectory for myasthenia gravis and CIDP, and after positive Pha…
- ▹VYVGART franchise expanding across MG/CIDP into rheumatology with positive Phase III ALKIVIA, supporting multi-indication platform breadth
- ▹~$4B OpEx and up to 5 US launches in 2027 signal aggressive growth investment but raise execution and spend-efficiency risk
Watchlist · 77/100Oct 22, 10:33 AM EDT
AbbVie's lutikizumab hits primary endpoint in Phase 3 hidradenitis suppurativa trial
ABBV
AbbVie reported positive topline Phase 3 results for lutikizumab in adults with hidradenitis suppurativa, with 31.4% of patients achieving HiSCR75 at week 16 versus 23.4% on comparator. The trial met its primary goal, supporting the drug's potential in a diffi…
- ▹Positive Phase 3 topline in hidradenitis suppurativa supports regulatory filing, but modest HiSCR75 delta (31.4% vs 23.4%) limits differentiation.
- ▹AbbVie's large immunology platform and commercial infrastructure de-risk launch, though lutikizumab is one of several pipeline assets.
Neutral · 55/100Oct 22, 9:27 AM EDT
Biohaven's Vyglxia NDA Resubmission Accepted by FDA, Stock Jumps 36%
BHVN
The FDA has accepted Biohaven's resubmitted New Drug Application for Vyglxia (troriluzole) to treat spinocerebellar ataxia, with a Prescription Drug User Fee Act action date set for Q1 2027. The acceptance marks a critical regulatory step forward for the compa…
- ▹FDA acceptance of resubmitted NDA is a positive regulatory step, but prior rejection and long PDUFA date (Q1 2027) limit near-term upside.
- ▹Single-asset micro-cap with no commercialized product and uncertain reimbursement; high risk despite stock surge.
High Risk · 45/100Oct 22, 2:18 PM EDT
Moderna's Cancer Vaccine Data Leak Sends Shares Tumbling
MRNAMRK
Moderna shares plunged after leaked data from an ongoing cancer vaccine study raised concerns about efficacy. The full dataset was later released by ESMO, and Moderna and partner Merck issued a news release. Investors are closely watching analyst reactions to…
- ▹Leaked cancer vaccine data likely shows disappointing efficacy, raising doubts about the mRNA platform's oncology potential.
- ▹Negative data readout creates overhang and reduces confidence in the Moderna-Merck collaboration.
High Risk · 37/100Oct 22, 8:11 AM EDT
Celularity Clears Nasdaq Reporting Hurdle After Filing Delayed 10-Q
CELU
Celularity (CELU) received written confirmation from Nasdaq that it has regained compliance with listing rules requiring timely periodic financial reports. The determination follows the company's October 20, 2026 filing of its Form 10-Q for the quarter ended J…
- ▹Nasdaq compliance regained after delayed filings, but prior non-compliance signals governance and reporting risk
- ▹No pipeline, commercial, or regulatory catalysts; single-asset micro-cap with limited differentiation
High Risk · 27/100Oct 22, 9:25 AM EDT
Sunshine Biopharma Implements 1-for-20 Reverse Split to Satisfy Nasdaq Bid Price Rule
SBFM
Sunshine Biopharma (SBFM) announced a 1-for-20 reverse stock split effective October 26, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The split will reduce outstanding shares from 15.2 million to approximately 761,000. Investors shou…
- ▹Reverse split to avoid Nasdaq delisting signals severe financial distress and dilution risk
- ▹No pipeline, regulatory, or commercial catalysts; pure listing-compliance news